Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
58.36
+1.45 (2.55%)
At close: Mar 27, 2026
SHE:300049 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,595 | 1,342 | 1,147 | 1,001 | 891.56 |
Other Revenue | - | 7.49 | 6.9 | 7.37 | 6.93 |
| 1,595 | 1,349 | 1,154 | 1,009 | 898.48 | |
Revenue Growth (YoY) | 18.26% | 16.93% | 14.37% | 12.27% | 11.26% |
Cost of Revenue | 399.36 | 350.73 | 291.39 | 267.67 | 239.14 |
Gross Profit | 1,196 | 998.28 | 862.34 | 741.09 | 659.34 |
Selling, General & Admin | 675.19 | 584.24 | 527.56 | 474.49 | 405.7 |
Research & Development | 111.2 | 99.49 | 82.47 | 70.82 | 64.79 |
Other Operating Expenses | 10.23 | 8.08 | 10.43 | 10.79 | 12.5 |
Operating Expenses | 796.63 | 711.59 | 622 | 562.68 | 491.94 |
Operating Income | 399.4 | 286.69 | 240.34 | 178.41 | 167.4 |
Interest Expense | - | -2.77 | -0.9 | -1.58 | -2.33 |
Interest & Investment Income | - | 16.07 | 12.38 | 9.73 | 10.54 |
Currency Exchange Gain (Loss) | - | 10.37 | -2.31 | 7.93 | 16.48 |
Other Non Operating Income (Expenses) | -32.54 | -2.03 | 4.08 | -1.28 | -0.26 |
EBT Excluding Unusual Items | 366.87 | 308.34 | 253.59 | 193.21 | 191.83 |
Impairment of Goodwill | - | -7.7 | - | - | - |
Gain (Loss) on Sale of Investments | 16.83 | -23.11 | - | - | - |
Gain (Loss) on Sale of Assets | 0.38 | -0.31 | -0.82 | -1.86 | -3.46 |
Asset Writedown | -33.52 | -0 | -4.71 | -0 | - |
Other Unusual Items | - | -6.66 | -12.66 | 0.29 | 0.77 |
Pretax Income | 350.56 | 270.55 | 235.4 | 191.63 | 189.14 |
Income Tax Expense | 92.14 | 74.67 | 58.29 | 46.22 | 41.1 |
Earnings From Continuing Operations | 258.42 | 195.88 | 177.11 | 145.41 | 148.04 |
Minority Interest in Earnings | -104.33 | -82.59 | -75.55 | -47.52 | -52.57 |
Net Income | 154.09 | 113.29 | 101.56 | 97.89 | 95.47 |
Net Income to Common | 154.09 | 113.29 | 101.56 | 97.89 | 95.47 |
Net Income Growth | 36.02% | 11.54% | 3.75% | 2.54% | 54.22% |
Shares Outstanding (Basic) | 266 | 264 | 263 | 263 | 260 |
Shares Outstanding (Diluted) | 266 | 264 | 263 | 263 | 260 |
Shares Change (YoY) | 0.49% | 0.50% | -0.01% | 1.30% | 1.31% |
EPS (Basic) | 0.58 | 0.43 | 0.39 | 0.37 | 0.37 |
EPS (Diluted) | 0.58 | 0.43 | 0.39 | 0.37 | 0.37 |
EPS Growth | 35.36% | 10.98% | 3.76% | 1.22% | 52.22% |
Free Cash Flow | 162.51 | 2.44 | 115.66 | 98.69 | 142.94 |
Free Cash Flow Per Share | 0.61 | 0.01 | 0.44 | 0.38 | 0.55 |
Dividend Per Share | - | - | - | 0.200 | - |
Gross Margin | 74.97% | 74.00% | 74.74% | 73.47% | 73.38% |
Operating Margin | 25.04% | 21.25% | 20.83% | 17.69% | 18.63% |
Profit Margin | 9.66% | 8.40% | 8.80% | 9.70% | 10.63% |
Free Cash Flow Margin | 10.19% | 0.18% | 10.03% | 9.78% | 15.91% |
EBITDA | 478.18 | 358.88 | 307.52 | 236.39 | 221.12 |
EBITDA Margin | 29.97% | 26.60% | 26.65% | 23.43% | 24.61% |
D&A For EBITDA | 78.78 | 72.19 | 67.18 | 57.98 | 53.71 |
EBIT | 399.4 | 286.69 | 240.34 | 178.41 | 167.4 |
EBIT Margin | 25.04% | 21.25% | 20.83% | 17.69% | 18.63% |
Effective Tax Rate | 26.28% | 27.60% | 24.76% | 24.12% | 21.73% |
Revenue as Reported | - | 1,349 | 1,154 | 1,009 | 898.48 |
Advertising Expenses | - | 3.34 | 4.76 | 9.83 | 9.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.